ArticleBone marrow transplantation2016
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.Bone marrow transplantation · 2017Trial
- The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2024Review
- Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2023Review
- [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.Bone marrow transplantation · 2021Review
- Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.Annals of translational medicine · 2021Review
- The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.Frontiers in immunology · 2021Review
- Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation.OncoTargets and therapy · 2021Article
- Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.Frontiers in immunology · 2021Article
- The Role of Immune Checkpoints after Cellular Therapy.International journal of molecular sciences · 2020Review
- Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.Kidney international reports · 2020Article
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.Journal of cancer research and clinical oncology · 2019Review
- Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.Experimental hematology & oncology · 2019Article
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Review
- Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.AIDS research and human retroviruses · 2018Article
- Association between GvHD and nivolumab in the FDA adverse event reporting system.Bone marrow transplantation · 2017Article
- MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.Bone marrow transplantation · 2017Article
- Article
- Review
- Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26551782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.